Table 2.
Treatment characteristics before 125I seed implantation (n = 10)
| Previous treatment | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | Gender | Age (years) | Stagea | Pathology | Position of implant seeds (recurrent position) | Surgery (times) | EBRT (courses) | Previous cumulative dose (Gy) | Chemotherapy (cycles) | Recurrent timeb (months) |
| 1 | F | 16 | T1aN0M0G1 | Fibrosarcoma | Right axilla | 1 | 1 | 60 | 0 | 12 |
| Right upper arm | ||||||||||
| 2 | M | 20 | T1aN1M0G1 | Fibrosarcoma | Left neck and left supraclavicular | 2 | 1 | 60 | 0 | 24 |
| Before the left clavicle | ||||||||||
| left carotid artery | ||||||||||
| 3 | F | 19 | T2bN0M1G2 | Fibrosarcoma | Maxillofacial and right eye socket | 1 | 0 | 0 | 0 | 17 |
| 4 | M | 4 | T1bN0M0G2 | Alveolar soft tissue sarcoma | Left tongue root | 0 | 1 | 57.5 | 16 | 10 |
| Left tongue root and palatopharyngeal arch | ||||||||||
| 5 | M | 14 | T1bN0M0G1 | Fibrosarcoma | Right shoulder and neck | 1 | 1 | 58 | 0 | 8 |
| 6 | M | 20 | T1aN0M0G1 | Fibrosarcoma | Right chest wall | 4 | 0 | 0 | 0 | 72 |
| 7 | M | 9 | T1bN0M1G3 | Primitive neuroectodermal tumor | Left mandible | 1 | 0 | 0 | 12 | 17 |
| 8 | M | 16 | T2bN1M0G2 | Epithelioid sarcoma | Right thigh | 3 | 0 | 0 | 0 | 1 |
| 9 | F | 6 | T2bN0M1G2 | Rhabdomyosarcoma | Pelvic | 1 | 1 | 36 | 12 | 1 |
| 10 | M | 11 | T2bN1M0G2 | Alveolar soft tissue sarcoma | Right face | 0 | 1 | 33 | 12 | 4 |
aTumor node metastasis (TNM) stage according to the American Joint Committee on Cancer Staging Manual (2010); bRecurrent time is the interval between seed implantation and the last treatment